| CAS No.: | 132539-06-1 |
|---|---|
| Formula: | C17h20n4s |
| EINECS: | 603-618-4 |
| Type: | Pharmaceutical Intermediates |
| Appearance: | Powder |
| Quality: | Pharmaceutical Grade |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Olanzapine |
| CAS NO. | 132539-06-1 |
| Purity | 99% |
| Melting Point | 195 C |
| Appearance and shape | Light yellow crystal powder |
Olanzapine is a new atypical neuroleptic, binds to dopamine receptors, 5-HT receptors, and cholinergic receptors and has antagonistic effects. Antagonizing the D2 receptor is associated with the treatment of positive symptoms of schizophrenia; antagonizing the 5-HT2A receptor is associated with the treatment of negative symptoms of schizophrenia. This product does not cause granulocytic leukemia, no delayed complications and severe symptoms of mental depression. Oral absorption is good, food has no effect on its absorption rate, and peak plasma concentration can be reached 5 to 8 hours after oral administration. Mainly in the liver metabolism, about 75% of this product is excreted in the form of metabolites from the urine.
Function
Suitable for the acute phase and maintenance treatment of schizophrenia and other psychoses with severe positive and/or negative symptoms; It also relieves the common secondary affective symptoms of schizophrenia and related diseases.
Application
Olanzapine also known as olanzapine, olanzapine Oran, is a common antipsychotic drugs, clinically used to control schizophrenia, bipolar mania and agitation symptoms of dementia, it can significantly improve schizophrenia negative (for example: apathy, emotional and social withdrawal, poverty of speech), positive symptoms (such as: delusions, hallucinations, thought disorder, hostility and suspicion), and it may also relieve common secondary schizophrenia and related disorders affective symptoms.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}